We have developed a direct enzyme immunoassay (EIA) for quantifying immunoreactive 11-keto-thromboxane B2 (iKTXB) in unprocessed human urine. Cross-reactivity with other thromboxane metabolites and prostanoidswas negligible. Analytical recovery of 11-keto-TXB2 in urine specimens was 97.4% to 99.8%. Total imprecisionfor two clinical specimens was 8.5% and 12.2%. Intake of acetylsalicylicacid decreased the measured concentration of iKTXB. Cardiopulmonary bypass, a procedure known to activate platelets, increased the mean excretion rate of iKT)(B 10-fold. Simultaneous gas chromatography-mass spectrometry analysis of 11-keto-TXB2 and 11-keto-2,3-dinor TXB2 in urine specimens (n 17) from healthy subjects indicated that urinary iKTXB concentrations measured by EIA represented a sum of the two 11-keto metabolites. We conclude that the direct EIA is sufficiently sensitive, rapid, simple, and specificto allow screening for alterations in thromboxane biosynthesis in patients. TXA2 stimulates secondary platelet aggregation and secretion and takes part in the renal autoregulation.
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IndexingTerms:platelets . coagulation thrombosis
Thromboxane A2 (TXA2) is formed from arachidonic acid in several cell types.6 Under physiological conditions, platelets are the quantitatively most important source of TXA2, with small amounts also being formed in the kidneys and monocytes.
TXA2 stimulates secondary platelet aggregation and secretion and takes part in the renal autoregulation.
The major breakdown products of TXA2 are thromboxane B2 (TXB2), 2,3-dinor-TXB2, 11-keto-TXB2, and 11-keto-2,3-dinor-TXB2, all of which are found in human urine (1) ECDI, N-ethyl-N'-(dimethylamunopropyl)carbodiimide hydrochloride; PBS, phosphate-buffered saline; POD, horseradish peroxidase; SMCC, succinimidyl 4-(N-maleimidomethyl) cyclohaxane carboxylate; USA, bovine serum albumin; GC-MS, gas chromatography-mass spectrometry MDC, minimal detectable concentration; ABA, acetylsalicylic acid; and RMSE, root-mean-squared error.
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platelet activation or turnover, such as thrombosis in various parts of the body, e.g., coronary artery thrombosis and deep venous thrombosis (2, 3). Clinical use of such assays is hindered by the fact that available assays take several hours todays to complete and may require specialized equipment or preprocessing of the urine (4-10). Furthermore, so far, no direct immunoassay has been convincingly shown to give valid results in urine specimens obtained from human subjects under relevant clinical conditions, i.e., inhibition or stimulation of TXA2 turnover.
We describe here the development and validation of a rapid, direct, competitive enzyme imniunoassay (ETA) for measuring the sum of two main metabolites of TXA2, namely, 11-keto-TXB2
and 11-keto-2,3-dinor-TXB2.
Materials and Methods Preparationof 11-Keto-TXB2 Immune-Stimulating Complexes
Immune-stimulating complexes (ISC) containing 11- 1. To transform all molecules to the #{246}-lactone form, we incubated 1.0 mg (2.71 tmol) of 11-keto-TXB2 with 100 pL of glacial acetic acid for 1 h at ambient temperature, then evaporated the acetic acid under a stream of N2. The residue was washed two times with 1.0 mL of methanol, and the methanol was also evaporated under N2.
2. The 11-keto-TXB2 residue was dissolved in 50 1L of dimethylformssnide, and 1.55 imol of MDP was added in a volume of 50 pL. To form amide bonds between the carboxy groups in 11-keto-TXB2
and MDP, and amino groups in KLH (see below), we added 4.7 mol of N-hydroxybenzotriazole (HOBt) in 94 pL of dimethylformamide, and 4.7 p.mol of N-ethyl-N'-(dimethylaminopropyl)carbodiimide hydrochloride (ECDI), also in 94 L of dimethylformamide, to the 11-keto-TXBIMDP solution. The 11-keto-TXB1iMDP/HOBtJECDI solution was incubated for 1 h at ambient temperature.
3.
We then added this solution (in 10 aliquots of 30 jL)toadarkglassvialcontauning2.0mgofKLHin
1.2 mL of 0.1 mol/L NaHCO3 buffer, pH 8.5 (± 0.05), with continuous vigorous mixing. The mixture was incubated for 3 h at ambient temperature.
Finally, 1.5 mL of phosphate-buffered saline (PBS; 0.1 molIL sodium phosphate buffer, pH 7.5,0.15 mol/L sodium chloride) was added to the vial containing the 11-keto-TXB2IMDP/HOBtI ECDI/KLH.
The ISC samples containing 11-keto-TXB2
were stored in 100-L aliquots at -20 #{176}C.
Immunization of Rabbits
To immunize each of eight rabbits, we diluted 100 pL of ISC with 900 L of PBS. The ISC/PBS solution was mixed with 1.0 mL of incomplete Freund's adjuvant. The mixture was injected subcutaneously at four different sites, -0.5 mL at each site. The immunization was repeated at weeks 3 and 6 and every 4 weeks thereafter. After the third immunization, the rabbits were bled 1 week after each booster immunization.
Blood was collected in tubes containing Na4EDTA and indomethacin (approximate final concentrations 28 mmol/L and 15 mol/L, respectively).
The anticoagulated blood was centrifuged at 2000 x g at 4#{176}C immediately after bleeding. The antibody-containing plasma was stored in aliquota at -20 #{176}C.
Purificationof tgG from Antibody-ContainingPlasma
The Potassium phosphate buffer, 0.1 mol/L, pH 7.0, was used for equilibration of the column and elution of the enzymeantibody conjugate. The fractions containing molecular masses in the range 235 to 470 kDa were pooled. The POD/IgG ratio in the pool was 2.7.
Preparation of 11 -Keto-TXB2---Bovine Serum Albumin
The "capture conjugate" was prepared as follows: 1. The methyl acetate of 1.0mg of 1 1-keto-TXB2 in 10 gIL methyl acetate was evaporated with N2. The 11-keto-TXB2 residue was washed three times with 0.5 mL of methanol.
Methanol was evaporated with N2.
The 11-keto-TXB2
residue was incubated with 100 jL of acetic acid (100%) for 1 hat ambient temperature. Acetic acid was evaporated with N2. The residue was washed two times with 0.5 mL of methanol.
3. The 11-keto-TXB2 (2.7 mol) was dissolved in 100 L of dimethylformamide, and 2.7 mol of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in 50 L of dimethylformamide was added. The mixture was incubated for 1 h at ambient temperature.
The dihydroquinohne forms a mixed anhydride with 11-keto-TXB2, and the mixed anhydride then reacts with amino groups in be-vine serum albumin (BSA) (see below), forming amide bonds.
4.
This solution was then added (in 10-L aliquots) to 0.27 iLmol (19 mg) of BSA in 1.5 mL of distilled water and incubated for 3 h at ambient temperature, with mild stirring. The conjugate was isolated by means of gel filtration on a small disposable column (PD-10; Pharmacia) equilibrated with PBS. The volume of the eluate, which contained the capture conjugate, was adjusted to 3.5 mL with PBS and stored in aliquots at -20 #{176}C.
Coatingof Plates with 11-Keto-TXB2---BSA
The 11-keto-DCB2--BSA capture conjugate was diluted to 20 mgIL in sodium carbonate/hydrogen carbonate buffer, pH 9.2 (± 1). Each well in the microtiter strip (Nunc, Roskilde, Denmark; code no. 473709) was incubated with 200 L of diluted capture conjugate overnight at ambient temperature.
Nonspecific binding sites in each well were then blocked by overnight incubation with 300 jL of blocking buffer (9 g/L NaC1, 60 g'L sorbitol, 5 gIL BSA, and 0.5 g/L sodium aside, pH 7.7 ± 0.1). After aspirating the blocking buffer from the wells, we added 25 pL of blocking buffer, covered the plate with an adhesive plastic foil, and stored the plate in a bag containing a 10 x 10cm cloth saturated withal gIL solution of the preservative Germall II.
Preparation of 11-Keto-TXB2 Calibrators
All calibrators were prepared gravimetrically: An approximate volume was pipetted in a preweighed vial, and the exact volume dispensed was calculated by dividing the weight of the solution in question by its density. The volume of the diluent needed to give the desired concentration was calculated and expressed as a mass by multiplication by the density of the diluent. The needed mass was then added by weighing.
First, 50 L of 11-keto-TXB2 in 10 g/L methyl acetate (Cayman Chemical, Ann Arbor, MI; cat. no. 19500) was diluted into glycine buffer (0.1 mol/L, pH 9.0) to give a stock solution containing 100 000 ng/mL. The stock solution was kept at ambient temperature overnight to ensure the opening of the lactone ring in 11-keto-TXB2.
The stock solution was further diluted in several steps in calibrator buffer (0.2 mol/L glycine buffer, pH 9.5, containing 1 g/L BSA, 50 g/L mannitol, and 50 mg/L thimerosal) to give calibrators with concentrations of 4.00, 2.00, 1.00, 0.500, 0.250, 0.125, and 0.00 igIL. The calibrators were freeze-dried and stored at 4#{176}C. Before use in the assay, the calibrators were reconstituted with distilled water. Fast assay. The fast version of the assay for iKTXB2 was carried out the same as the standard assay but with the following modifications:
StandardAssay for Immunoreactive11-Keto-TXB (iKTXB)
(a) preincubation was reduced from 60 to 5 miii; (b) incubation was reduced from 60 to 15 miii; (c) only two strips (corresponding to 24 wells) were handled in one setup (to reduce the risk of drift). showed the expected GC behavior and mass spectrum, in comparison with its C20 homolog, 11-keto-TXB2. The mass spectrum of 11-keto-2,3-dinor-TXB2
ImmunoaffinityExtraction
was similjir to that of 11-keto-TXB2, both being characterized by intense [M-penthfluorobenzyl] ions at m/z 483 and 511, respectively. This indicated the expected difference of 28 amu (two methylene units) between the C18 and C homologs. 11-Keto-2,3-dinor-TXB2 was standardized against 11-keto-TXB2 by using [2H4]11-keto-TXB2 as internal standard and by using selected ion recording of their carboxylate anions (m/z 483, 511, and 515, respectively).
[2H4]11-Keto-2,3-dunor-TXB2 was prepared from PHJ2,3-dinor-TXB2, as described above for the unlabeled compound. 
Measurementof

Results
Assay Performance
Calthration.
Curve fitting was performed by use of the MultiCalc software (Pharmacia), with a weighted fourparameter logistic plot. Figure 1 shows the calibration curves for the standard assay (2 h) and the fast assay (30 miii) of iKTXB. 
Normal Values
No proper reference interval was established. However, we collected urine specimens for 6.5 to 17 h from 17 apparently healthy women (ages 24 to 48). The range of urine volume collected was 0.170-1.00 L. The means (± SD) of measured concentration, excretion rate, and ratio of iKTXB (pg) to creatinine (g) were: 1.83 ± 1.43 pgfL, 1.15 ± 0.75 ng/mun, and 1.47 ± 0.92, respectively (n = 16). Data from one subject was excluded because her urine concentration of iKTXB was 7.9 SD above the mean for the remaining 16 subjects.
Biological Validation
Effect of a single dose of 500 mg of acetylsa.licylic acid (ASA) in normal subjects. Nine adult subjects volunteered to take a tablet containing 500 mg of ASA after voiding.
On the following morning a spot urine specimen was obtained from each subject. In all subjects a decrease Urinary excretion of metabolites of platelet-derived TXA2 metabolites is therefore progressively inhibited by repeated intake of 30 mg of ASA per day. We studied four healthy subjects (ages 25.5 ± 1.7 years, weight 74.5 ± 9.9 kg) before, during, and after oral administration of 30 mgofASAper day for 8 days (16). ASA was taken at 1100, immediately after voiding. Urine was collected from 1100 to 1700 for three consecutive days before aspirin intake (Bi to B3), on days 5 (AS) and 8 (AS) during ASA intake, and on days 1 (P1), 4 (P4), and 8 (P8) after the drug was discontinued.
The urine specimens were eyamined for iKTXB, 11-keto-TXB2, and 11-keto-2,3-dinor TXB2 (see also below). The urinary excretion of iKFXB decreased markedly in all four subjects during low-dose administration of ASA (Figure 3) . Effect of in vivo platelet activation. We evaluated 16 patients before and after cardiopulmonary bypass. Unnary excretion rates of iKTXB (mean ± 1 SEM) increased from 2.13 ± 0.34 to 23.4 ± 3.6 ng/min (17).
Method Comparison
In the first phase of the study, iKTXB2 values obtained by EIA were compared with 11-keto-TXB2 values obtained by GC-MS in 17 specimens obtained from pa- The cross-reactivity of 11-keto-2,3-dinor-TXB2
in the ELA was thereafter demonstrated as described above.
DIscussion
We have developed a sensitive direct enzyme inunu- We have furthermore shown that it is possible, with the available reagents and format (solid-phase ETA), to obtain reliable results within 30 mm. Use of a more appropriate assay format, with faster reaction kinetics (e.g., an immunoflitration assay), should give fully reliable results within 15 mm. The antibody we used in the ETA was developed by an immunization technique favoring production of high-affinity antibodies. The antibody was especially selected for its fast reaction kinetics, narrow specificity for 1 1-keto-TXB2-related compounds, and lack of undesired cross-reactivities.
Therefore, the development of the present assay may represent a significant step towards a clinically useful assay for the measurement of thromboxane metabolites in human urine.
We conclude that this direct ETA for urinary iKTXB results in very reliable estimates of the formation of 11-keto-TXB2 and 11-keto-2,3-dinor-TXB2 in the human body. The assay is rapid, simple, and sufficiently specific to allow the detection of alterations in thromboxane biosynthesis in human subjects.
